Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole

Clinical Infectious Diseases

Volumn 40, Issue 11, 2005, Pages 1586-1590

  Musher, Daniel M ^a,b,c   Aslam, Saima ^b   Logan, Nancy ^a   Nallacheru, Srikanth ^a   Bhaila, Imran ^d   Borchert, Franziska ^a   Hamill, Richard J ^a,b  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Department of Medicine ^*  (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d AGA KHAN UNIVERSITY   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

CEFEPIME; METRONIDAZOLE; MONOCLONAL ANTIBODY; NITAZOXANIDE; PROBIOTIC AGENT; TINIDAZOLE; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE; COLITIS; DRUG EFFICACY; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECURRENT DISEASE; REFRACTORY PERIOD; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; DRUG ADMINISTRATION SCHEDULE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FOLLOW-UP STUDIES; HUMANS; METRONIDAZOLE; PROSPECTIVE STUDIES; TREATMENT FAILURE; VANCOMYCIN;

EID: 19344364596     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/430311     Document Type: Article

References (33)

1. Johnson S, Gerding DN. Clostridium difficile-associated diarrhea. Clin Infect Dis 1998; 26:1027-34.
2. Mylonakis E, Ryan ET, Calderwood SB. Clostridium difficile-associated diarrhea: a review. Arch Intern Med 2001; 161:525-33.
3. Bartlett JG. Antibiotic-associated diarrhea. N Engl J Med 2002; 346:334-9.
4. Silva J Jr, Batts DH, Fekety R, Plouffe JF, Rifkin GD, Baird I. Treatment of Clostridium difficile colitis and diarrhea with vancomycin. Am J Med 1981; 71:815-22.
5. Bartlett JG. Treatment of antibiotic-associated pseudomembranous colitis. Rev Infect Dis 1984; 6(Suppl):S235-41.
6. Teasley DG, Gerding DN, Olson MM, et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet 1983; 2:1043-6.
7. Olson MM, Shanholtzer CJ, Lee JT Jr, Gerding DN. Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991. Infect Control Hosp Epidemiol 1994; 15:371-81.
8. Fekety R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 1997; 92:739-50.
9. Nair S, Yadav D, Corpuz M, Pitchumoni CS. Clostridium difficile colitis: factors influencing treatment failure and relapse - a prospective evaluation. Am J Gastroenterol 1998; 93:1873-6.
10. Noren T, Akerlund T, Back E, et al. Molecular epidemiology of hospital-associated and community-acquired Clostridium difficile infection in a Swedish county. J Clin Microbiol 2004; 42:3635-43.
11. Layton BA, McDonald LC, Gerding DN, Liedtke LA, Strausbaugh LJ. Changing patterns of Clostridium difficile disease: a report from infectious diseases physicians [abstract 563]. In: Program and abstracts of the 42nd Annual Meeting of the Infectious Diseases Society of America (Boston). Alexandria, VA: Infectious Diseases Society of America, 2004:150.
12. Gerding DN. Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimicrobial resistance problem. Clin Infect Dis 2004; 38:646-8.
13. McCusker ME, Harris AD, Perencevich E, Roghmann MC. Fluoroquinolone use and Clostridium difficile-associated diarrhea. Emerg Infect Dis 2003; 9:730-3.
14. Gaynes R, Rimland D, Killum E, et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis 2004; 38:640-5.
15. Poutanen SM, Simor AE. Clostridium difficile-associated diarrhea in adults. CMAJ 2004; 171:51-8.
16. McDonald LC, Killgore GE, Thompson A, Johnson S, Gerding DN, C. difficile Investigation Team. Emergence of an epidemic strain of Clostridium difficile in the United States, 2001-4: potential role for virulence factors and antimicrobial resistance traits [abstract LB-2]. In: Program and abstracts of the 42nd Annual Meeting of the Infectious Diseases Society of America (Boston). Alexandria, VA: Infectious Diseases Society of America, 2004:58.
17. Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004; 171:466-72.
18. Archibald LK, Banerjee SN, Jarvis WR. Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987-2001. J Infect Dis 2004; 189:1585-9.
19. Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001; 357:189-93.
20. Fekety R, McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Mulligan ME. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis 1997; 24:324-33.
21. Wanahita A, Goldsmith EA, Marino BJ, Musher DM. Clostridium difficile infection in patients with unexplained leukocytosis. Am J Med 2003; 115:543-6.
22. Wilcox MH, Freeman J, Fawley W, et al. Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of Clostridium difficile diarrhoea. J Antimicrob Chemother 2004; 54:168-72.
23. Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med 2002; 136:834-44.
24. Kyne L, Sougioultzis S, McFarland LV, Kelly CP. Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea. Infect Control Hosp Epidemiol 2002; 23:653-9.
25. Wilcox MH, Fawley W, Freeman J, Brayson J. In vitro activity of new generation fluoroquinolones against genotypically distinct and indistinguishable Clostridium difficile isolates. J Antimicrob Chemother 2000; 46:551-6.
26. Mulligan ME, Miller SD, McFarland LV, Fung HC, Kwok RY. Elevated levels of serum immunoglobulins in asymptomatic carriers of Clostridium difficile. Clin Infect Dis 1993; 16(Suppl):S239-44.
27. Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000; 342:390-7.
28. Shim JK, Johnson S, Samore MH, Bliss DZ, Gerding DN. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet 1998; 351:633-6.
29. Warny M, Vaerman JP, Avesani V, Delmee M. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun 1994; 62:384-9.
30. Pochapin M. The effect of probiotics on Clostridium difficile diarrhea. Am J Gastroenterol 2000; 95:S11-3.
31. Kink JA, Williams JA. Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect Immun 1998; 66:2018-25.
32. Aboudola S, Kotloff KL, Kyne L, et al. Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect Immun 2003; 71:1608-10.
33. Giannesca PJ, Warny M. Active and passive immunization against Clostridium difficile diarrhea and colitis. Vaccine 2004; 22:848-56.